Increased risk of gastrointestinal bleed.
Monitor for bleeding; consider gastroprotective agents or alternative analgesics.
Source: KDT 7e
SSRI · Antidepressant, Anxiolytic
Also known as Nexito Plus, Eslopam Plus, S-Cetapram Plus, Elpram Plus, D'citalopam Plus
Escitalopram selectively inhibits serotonin reuptake, increasing serotonin levels in the synaptic cleft, leading to antidepressant and anxiolytic effects over time. Clonazepam, a benzodiazepine, enhances the effect of gamma-aminobutyric acid (GABA) at GABAA receptors, resulting in rapid anxiolytic, sedative, muscle relaxant, and anticonvulsant properties. The combination provides immediate symptomatic relief of anxiety and panic through clonazepam while escitalopram works to address the underlying mood disorder. Combination rationale: This fixed-dose combination aims to provide rapid symptomatic relief of anxiety or panic through the immediate action of clonazepam, while escitalopram initiates its slower-acting but sustained antidepressant and anxiolytic effects. This approach helps manage acute symptoms during the initial latency period of SSRI action, potentially improving patient adherence and outcomes, particularly in conditions where severe anxiety or panic is prominent.
D (due to Clonazepam)
Both escitalopram and clonazepam are excreted into breast milk. Not recommended during breastfeeding due to potential for sedation, feeding difficulties, and withdrawal symptoms in the infant. A risk-benefit assessment should be performed if absolutely necessary, with careful monitoring of the infant.
Increased risk of gastrointestinal bleed.
Monitor for bleeding; consider gastroprotective agents or alternative analgesics.
Source: KDT 7e
Increased risk of gastrointestinal bleed.
Monitor for bleeding; consider gastroprotective agents or alternative analgesics.
Source: KDT 7e
Increased risk of gastrointestinal bleed.
Monitor for bleeding; consider gastroprotective agents or alternative analgesics.
Source: KDT 7e
Increased risk of gastrointestinal bleed.
Monitor for bleeding; consider gastroprotective agents or alternative analgesics.
Source: KDT 7e
Increased risk of gastrointestinal bleed.
Monitor for bleeding; consider gastroprotective agents or alternative analgesics.
Source: KDT 7e
Increased risk of gastrointestinal bleed.
Monitor for bleeding; consider gastroprotective agents or alternative analgesics.
Source: KDT 7e
Increased bleeding risk.
Exercise extra caution and monitor for signs of bleeding.
Source: G&G 14e
Increased risk of gastrointestinal bleed.
Monitor for bleeding; consider gastroprotective agents or alternative analgesics.
Source: KDT 7e
Increased risk of gastrointestinal bleed.
Monitor for bleeding; consider gastroprotective agents or alternative analgesics.
Source: KDT 7e
Increased risk of gastrointestinal bleed.
Monitor for bleeding; consider gastroprotective agents or alternative analgesics.
Source: KDT 7e
Increased risk of gastrointestinal bleed.
Monitor for bleeding; consider gastroprotective agents or alternative analgesics.
Source: KDT 7e
Increased risk of gastrointestinal bleed.
Monitor for bleeding; consider gastroprotective agents or alternative analgesics.
Source: KDT 7e
Continue into a citation-backed clinical answer with the drug context already attached.